Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Molecules ; 26(15)2021 Jul 27.
Article in English | MEDLINE | ID: mdl-34361686

ABSTRACT

Limonene is a monoterpene confined to the family of Rutaceae, showing several biological properties such as antioxidant, anti-inflammatory, anticancer, antinociceptive and gastroprotective characteristics. Recently, there is notable interest in investigating the pharmacological effects of limonene in various chronic diseases due to its mitigating effect on oxidative stress and inflammation and regulating apoptotic cell death. There are several available studies demonstrating the neuroprotective role of limonene in neurodegenerative diseases, including Alzheimer's disease, multiple sclerosis, epilepsy, anxiety, and stroke. The high abundance of limonene in nature, its safety profile, and various mechanisms of action make this monoterpene a favorable molecule to be developed as a nutraceutical for preventive purposes and as an alternative agent or adjuvant to modern therapeutic drugs in curbing the onset and progression of neurodegenerative diseases. This manuscript presents a comprehensive review of the available scientific literature discussing the pharmacological activities of limonene or plant products containing limonene which attribute to the protective and therapeutic ability in neurodegenerative disorders. This review has been compiled based on the existing published articles confined to limonene or limonene-containing natural products investigated for their neurotherapeutic or neuroprotective potential. All the articles available in English or the abstract in English were extracted from different databases that offer an access to diverse journals. These databases are PubMed, Scopus, Google Scholar, and Science Direct. Collectively, this review emphasizes the neuroprotective potential of limonene against neurodegenerative and other neuroinflammatory diseases. The available data are indicative of the nutritional use of products containing limonene and the pharmacological actions and mechanisms of limonene and may direct future preclinical and clinical studies for the development of limonene as an alternative or complementary phytomedicine. The pharmacophore can also provide a blueprint for further drug discovery using numerous drug discovery tools.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Antioxidants/therapeutic use , Biological Products/therapeutic use , Citrus/chemistry , Limonene/therapeutic use , Neurodegenerative Diseases/drug therapy , Neuroprotective Agents/therapeutic use , Phytotherapy/methods , Plant Extracts/therapeutic use , Animals , Biological Products/chemistry , Drug Discovery/methods , Humans , Oils, Volatile/chemistry , Oxidative Stress/drug effects
2.
Molecules ; 24(11)2019 Jun 10.
Article in English | MEDLINE | ID: mdl-31185705

ABSTRACT

Parkinson's disease, a chronic, age related neurodegenerative disorder, is characterized by a progressive loss of nigrostriatal dopaminergic neurons. Several studies have proven that the activation of glial cells, presence of alpha-synuclein aggregates, and oxidative stress, fuels neurodegeneration, and currently there is no definitive treatment for PD. In this study, a rotenone-induced rat model of PD was used to understand the neuroprotective potential of Lycopodium (Lyc), a commonly-used potent herbal medicine. Immunohistochemcial data showed that rotenone injections significantly increased the loss of dopaminergic neurons in the substantia nigra, and decreased the striatal expression of tyrosine hydroxylase. Further, rotenone administration activated microglia and astroglia, which in turn upregulated the expression of α-synuclein, pro-inflammatory, and oxidative stress factors, resulting in PD pathology. However, rotenone-injected rats that were orally treated with lycopodium (50 mg/kg) were protected against dopaminergic neuronal loss by diminishing the expression of matrix metalloproteinase-3 (MMP-3) and MMP-9, as well as reduced activation of microglia and astrocytes. This neuroprotective mechanism not only involves reduction in pro-inflammatory response and α-synuclein expression, but also synergistically enhanced antioxidant defense system by virtue of the drug's multimodal action. These findings suggest that Lyc has the potential to be further developed as a therapeutic candidate for PD.


Subject(s)
Brain/pathology , Dopaminergic Neurons/pathology , Inflammation/pathology , Lycopodium/chemistry , Oxidative Stress , Parkinson Disease/drug therapy , Parkinson Disease/pathology , Plant Extracts/therapeutic use , Animals , Antioxidants/metabolism , Catalase/metabolism , Cyclooxygenase 2/metabolism , Cytokines/metabolism , Disease Models, Animal , Dopaminergic Neurons/drug effects , Glutathione/metabolism , Inflammation Mediators/metabolism , Lipid Peroxidation/drug effects , Male , Malondialdehyde/metabolism , Matrix Metalloproteinases/metabolism , Microglia/drug effects , Microglia/metabolism , Nerve Degeneration/pathology , Neuroprotection/drug effects , Nitric Oxide/metabolism , Nitric Oxide Synthase Type II/metabolism , Nitrites/metabolism , Oxidative Stress/drug effects , Plant Extracts/pharmacology , Rats, Wistar , Rotenone , Superoxide Dismutase/metabolism , alpha-Synuclein/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL